LUND, SWEDEN – The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Clinical Laboratory licensure, allowing physicians in Rhode Island to order the IMMray™ PanCan-d test for their patients.
“Receiving licensure in Rhode Island now allows us to offer IMMray™ PanCan-d in 46 states. We expect additional state licensures to follow, as we work to make IMMray™ PanCan-d accessible to patients across the United States who are at risk for pancreatic cancer,” says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc., the US subsidiary of Immunovia AB.
For more information, please contact:Philipp MathieuActing CEO and PresidentEmail: philipp.mathieu@immunovia.com
Tobias BülowSenior Director Investor Relations and Corporate CommunicationsEmail: tobias.bulow@immunovia.comTel: +46 736 36 35 74
The information was submitted for publication on May 17, 2022, at 08:30 am CET.
